Cargando…

S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY

Detalles Bibliográficos
Autores principales:	Chapuis, Nicolas, Rombaut, David, Simoni, Yannick, Huang, Fei, Fontenay, Michaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428484/ http://dx.doi.org/10.1097/01.HS9.0000967588.88952.1a

Ejemplares similares

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Platzbecker, Uwe, et al.
Publicado: (2023)

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Santini, Valeria, et al.
Publicado: (2023)

S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES
por: Dussiau, Charles, et al.
Publicado: (2023)

S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA
por: Locatelli, Franco, et al.
Publicado: (2023)

Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications
por: Simoni, Yannick, et al.
Publicado: (2022)

S163: POLYSOME INTERACTOME IN RPS14-DEFICIENT CELLS REVEALS THE INVOLVEMENT OF THE MRNA DECAY MACHINERY IN TRANSLATION SELECTIVITY.
por: Tuerdi, Zubaidan, et al.
Publicado: (2023)

S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
por: Crisà, Elena, et al.
Publicado: (2023)

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis
por: Raimbault, Anna, et al.
Publicado: (2016)

S189: PROTEOGENOMIC LANDSCAPE OF MULTIPLE MYELOMA
por: Ramberger, Evelyn, et al.
Publicado: (2023)

S171: HIGHER MDMX EXPRESSION WAS ASSOCIATED WITH HYPOMETHYLATING AGENT RESISTANCE AND WORSE SURVIVAL IN MYELODYSPLASTIC SYNDROME PATIENTS, INFERRING IT A POTENTIAL THERAPEUTIC TARGET
por: Wang, Yu-Hung, et al.
Publicado: (2023)

S304: WHAT IS A MASSIVE TRANSFUSION? A SCOPING REVIEW TO INFORM AN INTERNATIONAL CONSENSUS DEFINITION
por: Lin, Victor, et al.
Publicado: (2023)

S271: AN UPDATED FOLLOW-UP OF BRL-101, CRISPR-CAS9-MEDIATED GENE EDITING OF THE BCL11A ENHANCER FOR TRANSFUSION-DEPENDENT BETA-THALASSE
por: Fu, Bin, et al.
Publicado: (2023)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
por: Komrokji, Rami S., et al.
Publicado: (2023)

P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS
por: Sekeres, Mikkael, et al.
Publicado: (2023)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

S272: SAFETY AND EFFICACY OF RM-001 IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA: EARLY RESULTS FROM THE ONGOING OF AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS
por: Liu, Rongrong, et al.
Publicado: (2023)

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
por: Leibundgut, Elisabeth Oppliger, et al.
Publicado: (2020)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

S166: KER-050 TREATMENT IMPROVED MARKERS OF ERYTHROPOIETIC ACTIVITY AND HEMATOPOIESIS OVER SIX MONTHS WHICH RESULTED IN HEMATOLOGICAL RESPONSES ACROSS A BROAD, LOWER-RISK MDS POPULATION
por: Giagounidis, Aristoteles, et al.
Publicado: (2023)

P169 Systemic Pythiosis: presumably, the first human case in India
por: Joe, Geethu, et al.
Publicado: (2022)

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
por: Tefferi, A, et al.
Publicado: (2016)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

S204: SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI-PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: 18-MONTH RESULTS OF A PHASE 2 STUDY
por: Valent, Jason, et al.
Publicado: (2023)

Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton
por: MENDER, ILGEN, et al.
Publicado: (2013)

S252: MODULATING HEMATOPOIESIS: ENGINEERING TPO VARIANTS WITH DISTINCT HEMATOPOIETIC FUNCTION
por: Masoumi, Zahra, et al.
Publicado: (2023)

S243: LACTATE PRODUCED BY T CELLS DURING AGVHD PROMOTES SECOND SIGNAL GENERATION FOR T CELL ACTIVATION THROUGH HISTONE MODIFICATION
por: Wu, Hengwei, et al.
Publicado: (2023)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
por: Della Porta, Matteo Giovanni, et al.
Publicado: (2023)

S295: TACROLIMUS MODULATES CD4+ T-CELL PROLIFERATION AND FUNCTION VIA MTHFD2 IN IMMUNE THROMBOCYTOPENIA
por: Yang, LI-Ping, et al.
Publicado: (2023)

S215: KEYNOTE-667: OPEN-LABEL, PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT-LINE CHEMOTHERAPY
por: Vinti, Luciana, et al.
Publicado: (2023)

Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors
por: Baerlocher, Gabriela M., et al.
Publicado: (2020)

S289: PPP1R1B BINDS IRON REGULATORY PROTEINS AND MODULATES IRON CELLULAR CONTENT
por: Calvo López, Laura, et al.
Publicado: (2023)

S169. THE IMPACT OF PSYCHOSIS IN ADOLESCENT-ONSET BIPOLAR DISORDER: A STRUCTURAL MRI STUDY
por: Llach, Cristian, et al.
Publicado: (2020)

WS05.04 SARS-CoV-2 infection is reduced in both immortalised and primary CFTR-modulated human bronchial epithelial cells
por: Lotti, V., et al.
Publicado: (2022)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
por: Costa, Luciano, et al.
Publicado: (2023)

Infections inhabituelles
Publicado: (2011)

Grippe A (H1N1) en réanimation
Publicado: (2010)

ECMO veinoveineuse
Publicado: (2013)

S106: METABOLIC PLASTICITY REVEALS A TARGETABLE VULNERABILITY IN LEUKEMIA
por: Andrieu, Guillaume, et al.
Publicado: (2023)

S247: ADDING RUXOLITINIB AND DECITABINE TO BU/CY CONDITIONING REGIMENS TO PROPHYLAXIS POST-TRANSPLANT RELAPSE IN HIGH-RISK AML IS SAFE AND EFFECTIVE: A PROSPECTIVE, PHASE II STUDY
por: Wei, Yujun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0r9lki0vib15te29lng4921heq